Kanjin Therapeutics
PrivateLast Round
Seed
Apr 27, 2026
Total Funding Raised
$330,000
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Kanjin Therapeutics is a biotechnology company developing advanced therapeutics to halt and potentially restore kidney function, with the goal of eliminating the need for dialysis.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Kanjin Therapeutics Comparables
Compare Kanjin Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| R1 Therapeutics | 81% | |
| Walden Biosciences | 81% | |
| Rege Nephro Co., Ltd. | 78% | |
Kanjin Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Apr 27, 2026 |
Kanjin Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Kyoto University Innovation Capital | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 27, 2026
$330K round led by Kyoto University Innovation Capital
Kanjin Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Kanjin Therapeutics's valuation, stock price, and market status.